CN113278067A - 一种新型冠状病毒猪源性免疫球蛋白的制备方法 - Google Patents
一种新型冠状病毒猪源性免疫球蛋白的制备方法 Download PDFInfo
- Publication number
- CN113278067A CN113278067A CN202110177600.5A CN202110177600A CN113278067A CN 113278067 A CN113278067 A CN 113278067A CN 202110177600 A CN202110177600 A CN 202110177600A CN 113278067 A CN113278067 A CN 113278067A
- Authority
- CN
- China
- Prior art keywords
- immunoglobulin
- plasma
- supernatant
- immune
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 69
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 69
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 88
- 238000000034 method Methods 0.000 claims abstract description 70
- 239000000047 product Substances 0.000 claims abstract description 46
- 230000003053 immunization Effects 0.000 claims abstract description 34
- 239000011265 semifinished product Substances 0.000 claims abstract description 19
- 241000282887 Suidae Species 0.000 claims abstract description 18
- 239000000427 antigen Substances 0.000 claims abstract description 16
- 102000036639 antigens Human genes 0.000 claims abstract description 16
- 108091007433 antigens Proteins 0.000 claims abstract description 16
- 239000013067 intermediate product Substances 0.000 claims abstract description 8
- 229940031551 inactivated vaccine Drugs 0.000 claims abstract description 7
- 210000002381 plasma Anatomy 0.000 claims description 53
- 238000002649 immunization Methods 0.000 claims description 32
- 239000006228 supernatant Substances 0.000 claims description 32
- 238000003756 stirring Methods 0.000 claims description 31
- 241000282898 Sus scrofa Species 0.000 claims description 29
- 230000003472 neutralizing effect Effects 0.000 claims description 23
- 239000002244 precipitate Substances 0.000 claims description 23
- 241000700605 Viruses Species 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 238000012795 verification Methods 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 238000001556 precipitation Methods 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 238000011534 incubation Methods 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 13
- 208000025721 COVID-19 Diseases 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 238000000926 separation method Methods 0.000 claims description 12
- 238000000108 ultra-filtration Methods 0.000 claims description 12
- 229960005486 vaccine Drugs 0.000 claims description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 238000001816 cooling Methods 0.000 claims description 10
- 238000000502 dialysis Methods 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 9
- 239000011259 mixed solution Substances 0.000 claims description 9
- 238000005070 sampling Methods 0.000 claims description 9
- 206010035664 Pneumonia Diseases 0.000 claims description 8
- 239000000539 dimer Substances 0.000 claims description 8
- 239000000178 monomer Substances 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 230000002779 inactivation Effects 0.000 claims description 7
- 230000036512 infertility Effects 0.000 claims description 7
- 239000002510 pyrogen Substances 0.000 claims description 7
- 239000011550 stock solution Substances 0.000 claims description 7
- 239000002699 waste material Substances 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000007865 diluting Methods 0.000 claims description 4
- 230000001900 immune effect Effects 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 241000282894 Sus scrofa domesticus Species 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 210000001715 carotid artery Anatomy 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 238000007689 inspection Methods 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 239000013049 sediment Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 2
- 241001678559 COVID-19 virus Species 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 239000000568 immunological adjuvant Substances 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 238000006386 neutralization reaction Methods 0.000 claims 1
- 238000002627 tracheal intubation Methods 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 230000008569 process Effects 0.000 description 11
- 238000011282 treatment Methods 0.000 description 9
- 230000008901 benefit Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 241000283073 Equus caballus Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000011031 large-scale manufacturing process Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 208000032467 Aplastic anaemia Diseases 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000007086 side reaction Methods 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 208000034657 Convalescence Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000002650 immunosuppressive therapy Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 241000710777 Classical swine fever virus Species 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 229940126656 GS-4224 Drugs 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000702619 Porcine parvovirus Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011359 convalescent plasma therapy Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
Abstract
Description
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110177600.5A CN113278067B (zh) | 2021-02-09 | 2021-02-09 | 一种新型冠状病毒猪源性免疫球蛋白的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110177600.5A CN113278067B (zh) | 2021-02-09 | 2021-02-09 | 一种新型冠状病毒猪源性免疫球蛋白的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113278067A true CN113278067A (zh) | 2021-08-20 |
CN113278067B CN113278067B (zh) | 2022-06-28 |
Family
ID=77275836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110177600.5A Active CN113278067B (zh) | 2021-02-09 | 2021-02-09 | 一种新型冠状病毒猪源性免疫球蛋白的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113278067B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111471103A (zh) * | 2020-03-20 | 2020-07-31 | 唐山怡安生物工程有限公司 | 一种新冠病毒(2019-nCOV)的异源抗体及其制备方法 |
CN111499736A (zh) * | 2020-04-28 | 2020-08-07 | 国药集团武汉血液制品有限公司 | 一种静注covid-19人免疫球蛋白的制备方法 |
CN111569058A (zh) * | 2020-06-18 | 2020-08-25 | 武汉生物制品研究所有限责任公司 | 一种SARS-CoV-2灭活疫苗及其制备方法 |
EP3715847A1 (en) * | 2020-02-20 | 2020-09-30 | Euroimmun Medizinische Labordiagnostika AG | A method and reagents for the diagnosis of sars-cov-2 |
CN111978394A (zh) * | 2020-07-13 | 2020-11-24 | 珠海龄值生物科技有限公司 | 用于covid-19患者特异性免疫疗法的多克隆制剂的制备方法 |
CN112010968A (zh) * | 2020-10-19 | 2020-12-01 | 英科博雅基因科技(天津)有限公司 | 快速提取covid-19患者康复期血浆用于制备免疫球蛋白g的方法 |
-
2021
- 2021-02-09 CN CN202110177600.5A patent/CN113278067B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3715847A1 (en) * | 2020-02-20 | 2020-09-30 | Euroimmun Medizinische Labordiagnostika AG | A method and reagents for the diagnosis of sars-cov-2 |
CN111471103A (zh) * | 2020-03-20 | 2020-07-31 | 唐山怡安生物工程有限公司 | 一种新冠病毒(2019-nCOV)的异源抗体及其制备方法 |
CN111499736A (zh) * | 2020-04-28 | 2020-08-07 | 国药集团武汉血液制品有限公司 | 一种静注covid-19人免疫球蛋白的制备方法 |
CN111569058A (zh) * | 2020-06-18 | 2020-08-25 | 武汉生物制品研究所有限责任公司 | 一种SARS-CoV-2灭活疫苗及其制备方法 |
CN111978394A (zh) * | 2020-07-13 | 2020-11-24 | 珠海龄值生物科技有限公司 | 用于covid-19患者特异性免疫疗法的多克隆制剂的制备方法 |
CN112010968A (zh) * | 2020-10-19 | 2020-12-01 | 英科博雅基因科技(天津)有限公司 | 快速提取covid-19患者康复期血浆用于制备免疫球蛋白g的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN113278067B (zh) | 2022-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111548413B (zh) | 一种抗新型冠状病毒的抗体及其制备方法与应用 | |
CN111471103A (zh) | 一种新冠病毒(2019-nCOV)的异源抗体及其制备方法 | |
CN105601736B (zh) | 一种抗呼吸道合胞病毒人免疫球蛋白及其制备方法 | |
CN107267466A (zh) | 一种大规模生产猪伪狂犬病灭活疫苗的方法 | |
CN111454354A (zh) | 抗2019-nCoV的抗体、制剂及其制备方法和应用 | |
CN109694410A (zh) | 马抗犬瘟热病毒免疫球蛋白F(ab’)2及制备方法 | |
CN101186647B (zh) | 鸡球虫高免卵黄抗体的制备方法 | |
MX2009002909A (es) | Vacuna de ipv-dpt. | |
CN105601735B (zh) | 一种静注巨细胞人免疫球蛋白及其制备方法 | |
CN110420325A (zh) | 精制多价抗蛇毒冻干血清及其制备方法 | |
CN113278067B (zh) | 一种新型冠状病毒猪源性免疫球蛋白的制备方法 | |
US3560611A (en) | Process for the manufacture of preparations rich in interferon | |
CN105669860B (zh) | 一种抗手足口病人免疫球蛋白及其制备方法 | |
CN101361973A (zh) | 一种治疗水痘的药物及其制备方法 | |
CN101502651A (zh) | 狂犬病、破伤风双效价人免疫球蛋白及其制备方法 | |
CN111978394B (zh) | 用于covid-19患者特异性免疫疗法的多克隆制剂的制备方法 | |
RU2438709C1 (ru) | Сыворотка против болезней крупного рогатого скота, вызываемых вирусами инфекционного ринотрахеита, парагриппа, рота, корона и диареи - болезни слизистых, полиспецифическая гипериммунная, способ профилактики и лечения болезней крупного рогатого скота, вызываемых вирусами инфекционного ринотрахеита, парагриппа, рота, корона и диареи - болезни слизистых | |
CN107304230A (zh) | 一种抗犬细小病毒精制抗体及其制备方法 | |
CN106563125A (zh) | 鸭甲肝病毒ⅲ型复合物活疫苗及其制备方法 | |
CN1250284C (zh) | 甲型肝炎灭活疫苗 | |
CN1796416A (zh) | 抗禽流感病毒免疫球蛋白、制备方法和其制剂 | |
CN109453371A (zh) | 一种羊痘、山羊传染性胸膜肺炎二联灭活疫苗及其生产方法 | |
CN1042493C (zh) | 人胎胸腺素的制备方法 | |
Yamamura et al. | Uncomplicated HL-A matched sibling bone marrow graft for combined immune deficiency | |
CN106110422B (zh) | 艾滋病免疫治疗吸附器 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210906 Address after: 430073 Room 569, Building B1, Biological Innovation Park, 666 High-tech Avenue, Donghu New Technology Development Zone, Wuhan City, Hubei Province Applicant after: WUHAN ZHONGSHENG YUJIN BIOLOGICAL MEDICINE Co.,Ltd. Address before: 430073 Room 569, Building B1, Biological Innovation Park, 666 High-tech Avenue, Donghu New Technology Development Zone, Wuhan City, Hubei Province Applicant before: WUHAN ZHONGSHENG YUJIN BIOLOGICAL MEDICINE Co.,Ltd. Applicant before: National Pharmaceutical Group animal health Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |